1. Microvascular disease confers additional risk to COVID-19 infection
- Author
-
Amy Lynn Doneen, David J. Vigerust, and Bradley Field Bale
- Subjects
0301 basic medicine ,Adult ,medicine.medical_specialty ,Aging ,Neutrophils ,MPO ,Disease ,Article ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Diabetes mellitus ,Internal medicine ,Case fatality rate ,Pandemic ,medicine ,Diabetes Mellitus ,Humans ,Child ,Lung ,Pandemics ,Peroxidase ,Innate immunity ,business.industry ,Microcirculation ,Cancer ,COVID-19 ,General Medicine ,Hydrogen Peroxide ,medicine.disease ,Pathophysiology ,Immunity, Innate ,United States ,Hypochlorous Acid ,Microvascular disease ,Pneumonia ,030104 developmental biology ,medicine.anatomical_structure ,Cardiovascular Diseases ,Hypertension ,Microvessels ,Disease Susceptibility ,business ,030217 neurology & neurosurgery - Abstract
The majority of fatalities thus far in the COVID-19 pandemic have been attributed to pneumonia. As expected, the fatality rate reported in China is higher in people with chronic pulmonary disease (6.3%) and those who have cancer (5.6%). According to the American College of Cardiology Clinical Bulletin "COVID-19 Clinical Guidance for the CV Care Team", there is a significantly higher fatality rate in people who are elderly (8.0% 70-79 years; 14.8% ≥80 years), diabetic (7.3%), hypertensive (6.0%), or have known cardiovascular disease (CVD) (10.5%). We propose a biological reason for the higher mortality risk in these populations that is apparent. We further present a set of pathophysiological reasons for the heightened danger that could lead to therapies for enhanced management and prevention.
- Published
- 2020